Similarly, another biallelic EIF2AK4 mutation was reported [c.1392delT(p.Arg465fs)], where the PVOD patient demonstrated compliance with PAH-targeted drugs [10]. Here, EIF2AK4 is linked to pulmonary arterial hypertension.